Everolimus plus exemestane in postmenopausal patients with HR(+. Everolimus Plus Exemestane in Postmenopausal Patients with HR+. Everolimus for Advanced Breast Cancer: An Update - Cancer Network.
BOLERO-2: Efficacy and safety of first-line everolimus plus. The BOLERO-2 study confirms everolimus and exemestane in ER.
25 Oct 2013 Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data demonstrated that everolimus and exemestane significantly prolonged. Background: In the BOLERO-2 study, progression-free survival (PFS) was significantly longer with the combination of everolimus and exemestane (EVE + EXE). 26 Sep 2011 The BOLERO-2 study confirms everolimus and exemestane in ER/PR+ advanced breast cancer improves PFS.
BOLERO-2 Study: Everolimus-Exemestane Overcomes Al Resistanc
18 Sep 2012 The 18-month results of the phase III BOLERO-2 trial were presented at the ASCO Breast Cancer Symposium, confirming earlier survival.
Everolimus in Postmenopausal Hormone-Receptor–Positive
Everolimus Plus Exemestane in Postmenopausal Patients with HR+. Everolimus for Advanced Breast Cancer: An Update - Cancer Network. 18 Sep 2012 The 18-month results of the phase III BOLERO-2 trial were presented at the ASCO Breast Cancer Symposium, confirming earlier survival.
The BOLERO-2 study confirms everolimus and exemestane in ER. Everolimus plus exemestane in postmenopausal patients with HR(+.
BOLERO-2: Efficacy and safety of first-line everolimus plus.
25 Oct 2013 Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data demonstrated that everolimus and exemestane significantly prolonged. 25 Oct 2013 Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data Background: In the BOLERO-2 study, progression-free survival (PFS) was significantly longer with the combination of everolimus and exemestane (EVE + EXE).
Inga kommentarer:
Skicka en kommentar
Obs! Endast bloggmedlemmar kan kommentera.